Posted by Michael Wonder on 16 Aug 2023
US FDA approves Ipsen’s Sohonos (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
16 August 2023 - Sohonos may be prescribed immediately in the US for eligible patients, aged 8 years and older for females and 10 years and older for males.
Ipsen announced today approval by the US FDA of Sohonos (palovarotene) capsules as a retinoid indicated for the reduction in volume of new heterotopic ossification in adults and paediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva.
